Synapse - Howard Scher

Results (1130)

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Ryan, C. J.; Abida, W.; Bryce, A. H.; Balar, A. V.; Dumbadze, I.; Given, R. W.; Morris, D.; Petrylak, D. P.; Redfern, C. H.; Scher, H. I.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression

Meeting Abstract

Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Consensus statement on circulating biomarkers for advanced prostate cancer

Meeting Abstract

Sumanasuriya, S.; Omlin, A. G.; Armstrong, A. J.; Attard, G.; Chi, K. N.; Bevan, C. L.; Waugh, D. J.; Ijzerman, M. J.; De Laere, B.; Lolkema, M. P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Abida, W.; Bryce, A. H.; Balar, A. V.; Chatta, G. S.; Dawson, N. A.; Guancial, E. A.; Hussain, A.; Jha, G. G.; Lipsitz, D. U.; Patnaik, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Consensus on molecular imaging and theranostics in prostate cancer

Journal Article

Fanti, S.; Minozzi, S.; Antoch, G.; Banks, I.; Briganti, A.; Carrio, I.; Chiti, A.; Clarke, N.; Eiber, M.; De Bono, J.; more...
Lancet Oncology (2018)

Fulltext@MSK | Save

Lessons from the SWITCH trial: Changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

Journal Article

Teo, M. Y.; Scher, H. I.
British Journal of Cancer (2018)

Fulltext@MSK | Save

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Journal Article

Rodrigues, D. N.; Rescigno, P.; Liu, D.; Yuan, W.; Carreira, S.; Lambros, M. B.; Seed, G.; Mateo, J.; Riisnaes, R.; Mullane, S.; more...
Journal of Clinical Investigation (2018)

Fulltext@MSK | Save

Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial

Journal Article

Autio, K. A.; Dreicer, R.; Anderson, J.; Garcia, J. A.; Alva, A.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Graf, R. P.; more...
JAMA Oncology (2018)

Fulltext@MSK | Save

Reproducibility and repeatability of semiquantitative (18)F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study

Journal Article

Vargas, H. A.; Kramer, G. M.; Scott, A. M.; Weickhardt, A.; Meier, A. A.; Parada, N.; Beattie, B. J.; Humm, J. L.; Staton, K. D.; Zanzonico, P. B.; more...
Journal of Nuclear Medicine (2018)

Fulltext@MSK | Save